https://www.selleckchem.com/pr....oducts/Temsirolimus.
A clinical response was observed during the maintenance period in 71.4 % of patients, their infliximab levels were significantly higher than in non-responders (6.3 µg/mL [IQR 6.7] vs 1.0 µg/mL [IQR 5.0], respectively; p = 0.016). Likewise, 53.6 % of patients achieved biochemical remission (responders 6.2 µg/mL [IQR 5.2] vs non-responders 3.2 µg/mL [IQR 5.0]; p = 0.031). CONCLUSION less than half of patients had target infliximab levels during the induction period. Therapeutic drug monitoring during this period is related to the ach
Like
Comment
Share
